Journal of the American Academy of Dermatology

Papers
(The H4-Index of Journal of the American Academy of Dermatology is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases608
Skin damage among health care workers managing coronavirus disease-2019353
COVID-19 can present with a rash and be mistaken for dengue312
The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries266
Varicella-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients261
Immune checkpoint inhibitor–related dermatologic adverse events216
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial208
Hidradenitis suppurativa197
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies180
A dermatologic manifestation of COVID-19: Transient livedo reticularis166
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated163
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, l155
Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries151
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis144
Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society142
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies136
Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak130
Should biologics for psoriasis be interrupted in the era of COVID-19?128
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series127
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures125
Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”121
Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France118
Chilblain-like acral lesions during the COVID-19 pandemic (“COVID toes”): Histologic, immunofluorescence, and immunohistochemical study of 17 cases115
Oral minoxidil treatment for hair loss: A review of efficacy and safety112
COVID-19 and racial disparities109
Skin color in dermatology textbooks: An updated evaluation and analysis106
Ultraviolet germicidal irradiation: Possible method for respirator disinfection to facilitate reuse during the COVID-19 pandemic105
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study104
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 103
Acne vulgaris and risk of depression and anxiety: A meta-analytic review102
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review100
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata98
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results91
Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic88
Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation88
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 i87
Cutaneous manifestations in COVID-19: Lessons learned from current evidence87
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent87
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features85
Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee84
COVID-19 and immunomodulator/immunosuppressant use in dermatology84
Prurigo nodularis84
Reply to “COVID-19 can present with a rash and be mistaken for dengue”: Petechial rash in a patient with COVID-19 infection84
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)83
United States burden of melanoma and non-melanoma skin cancer from 1990 to 201980
Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens79
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence79
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 79
The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities79
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients77
Clinical effectiveness and cost-effectiveness of teledermatology: Where are we now, and what are the barriers to adoption?77
Prurigo nodularis76
Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review75
Leprosy: Clinical aspects and diagnostic techniques75
Visible light. Part I: Properties and cutaneous effects of visible light74
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 72
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic derm72
Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment71
Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits71
Teledermatology in the era of COVID-19: Experience of an academic department of dermatology70
Pathophysiologic mechanisms of itch in bullous pemphigoid70
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis70
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study70
Field cancerization: Definition, epidemiology, risk factors, and outcomes70
Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study69
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations69
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials68
Hidradenitis suppurativa67
0.049174070358276